Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chougule, Mahavir B ^a   Patel, Apurva ^b   Sachdeva, Pratik ^b   Jackson, Tanise ^b   Singh, Mandip ^b  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; GEMCITABINE; NOSCAPINE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ANTITUSSIVE AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITUSSIVE AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELLS, CULTURED; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NOSCAPINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81055125711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027394     Document Type: Article

References (49)

1. Hecht SS, (1999) Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91: 1194-1210.
2. American Cancer Society website. Available: http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-key-statistics. Accessed 2011 Oct 28.
3. Sheth S, (2010) Current and emerging therapies for patients with advanced non-small-cell lung cancer. Am J Health Syst Pharm 67: S9-14.
4. Wakelee H, Belani CP, (2005) Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 (Suppl 3): 1-10.
5. Douillard JY, Eckardt J, Scagliotti GV, (2002) Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer 38 (Suppl 4): 21-28.
6. Klastersky J, Awada A, (1997) [Gemcitabine: a new chemotherapy agent for solid cancers]. Rev Med Brux 18: 328-334.
7. Dougherty DW, Friedberg JW, (2010) Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? Curr Hematol Malig Rep 5: 148-156.
8. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552.
9. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, et al. (2010) Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 126: 1235-1245.
10. Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P, (2008) Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs 26: 407-415.
11. Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, et al. (2005) Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 92: 681-689.
12. Denlinger CE, Rundall BK, Keller MD, Jones DR, (2004) Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78: 1207-1214 discussion 1207-1214.
13. Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, et al. (2009) Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 9: 250.
14. Jordan MA, (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2: 1-17.
15. van Zuylen L, Verweij J, Sparreboom A, (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19: 125-141.
16. Markman M, (2003) Managing taxane toxicities. Support Care Cancer 11: 144-147.
17. Anderson JT, Ting AE, Boozer S, Brunden KR, Crumrine C, et al. (2005) Identification of novel and improved antimitotic agents derived from noscapine. J Med Chem 48: 7096-7098.
18. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, et al. (2006) Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 107: 2486-2492.
19. Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, et al. (2002) Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 62: 4109-4114.
20. Zhou J, Gupta K, Yao J, Ye K, Panda D, et al. (2002) Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 277: 39777-39785.
21. Heidari N, Goliaei B, Moghaddam PR, Rahbar-Roshandel N, Mahmoudian M, (2007) Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 18: 1139-1147.
22. Landen JW, Hau V, Wang M, Davis T, Ciliax B, et al. (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 10: 5187-5201.
23. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, et al. (1998) Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A 95: 1601-1606.
24. Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M, (2008) Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 63: 117-126.
25. Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M, (2011) Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer 71: 271-282.
26. Chougule MB, Patel AR, Jackson T, Singh M, (2011) Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS One 6: e17733.
27. Hiser L, Herrington B, Lobert S, (2008) Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro. Leuk Lymphoma 49: 1603-1609.
28. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, et al. (2009) Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 15: 543-552.
29. Menendez JA, del Mar Barbacid M, Montero S, Sevilla E, Escrich E, et al. (2001) Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 37: 402-413.
30. Zhao L, Wientjes MG, Au JL, (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994-8004.
31. Xu G, Pan J, Martin C, Yeung SC, (2001) Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86: 1769-1777.
32. Newcomb EW, Lukyanov Y, Alonso-Basanta M, Esencay M, Smirnova I, et al. (2008) Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys 71: 1477-1484.
33. Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, et al. (2008) Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7: 638-647.
34. Guo Q, Chen Y, Wu Y, (2009) Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1. Tumori 95: 796-803.
35. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, et al. (2009) Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther 8: 980-987.
36. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, et al. (2010) Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293: 99-108.
37. Zupi G, Scarsella M, D'Angelo C, Biroccio A, Paoletti G, et al. (2005) Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther 4: 866-871.
38. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G, (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35: 796-807.
39. Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Alm AT, (1990) Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 39: 275-279.
40. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, et al. (2007) Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 60: 831-839.
41. Dahlstrom B, Mellstrand T, Lofdahl CG, Johansson M, (1982) Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol 22: 535-539.
42. Yao JC, Wang L, Wei D, Gong W, Hassan M, et al. (2004) Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10: 4109-4117.
43. Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, et al. (2004) Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 25: 461-468.
44. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, et al. (2005) Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 65: 1007-1017.
45. Abdelrahim M, Safe S, (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68: 317-329.
46. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, et al. (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032.
47. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, et al. (2009) Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30: 1193-1201.
48. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC, (2007) p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 67: 3862-3870.
49. Schniewind B, Heintz K, Kurdow R, Ammerpohl O, Trauzold A, et al. (2006) Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. J Carcinog 5: 25.